Guo Ruyue, Shen Xiaoming, Ealing John, Zhou Jiao, Lu Jin, Ning Yunfan
Department of Encephalopathy, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, China.
The First Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou, China.
Front Dement. 2024 Jul 3;3:1380221. doi: 10.3389/frdem.2024.1380221. eCollection 2024.
To systematically evaluate the efficacy of acupuncture in the treatment of cognitive impairment in Alzheimer's disease (AD) by meta-analysis, in order to provide evidence-based evidence for the application of acupuncture therapy in the clinical process of AD.
From the establishment of the database to December 31, 2022, China Biomedical Literature Database (CBM), China National Knowledge Network (CNKI), VIP database, WanFang Database, Pubmed, Embase and Cochrane Library Database were systematically searched. To collect published randomized controlled clinical trials (RCTS) of acupuncture in the treatment of cognitive impairment in AD. The subjects in the intervention group were given acupuncture alone or combined with other treatments the same as the control group; the control group received conventional Western medicine treatment. The main outcome indicators of the study were cognitive function assessment of subjects, including: Simple Mental State Examination Scale (MMSE), Assessment of daily Living Ability Scale (ADL), Alzheimer's Disease Cognitive Function Assessment Scale (ADAS-Cog), TCM syndrome score (SDSD), Montreal Cognitive Test (MoCA), Secondary outcome indicators were the occurrence of adverse reactions. Literature screening, data extraction, and quality evaluation of the included literature were performed independently by two researchers, according to bias risk assessment tools recommended in the Cochrane manual. Data were analyzed by RevMan5.3 software. Dichotomous variables were represented by risk ratio (OR) and 95% CI, and continuity variables were represented by mean difference (MD) and 95% CI. For heterogeneity analysis, when > 0.1 and ≤ 50%, fixed effect model was applied. When ≤ 0.1 and > 50%, the random effects model is applied.
A total of 1,172 eligible subjects were included in 18 RCTS, including 595 in the intervention group and 577 in the control group. The results of meta-analysis are as follows: acupuncture intervention group improved MMSE [MD = 1.67, 95% CI (0.94, 2.41), < 0.00001], ADL [MD = -1.18, 95% CI (-3.09, 0.72), = 0.22], ADAS-Cog [MD = 3.31, 95% CI (5.84, 0.78), = 0.01], SDSD [MD = 2.40, 95% CI (3.53, 1.26), < 0.0001], MoCA [MD = 4.80, 95% CI (3.74, 5.86), = 0.04] were better than the control group. No serious adverse reactions related to acupuncture were observed in the intervention group, and the incidence and severity of adverse reactions were lower than those in the control group, with statistical significance [OR = 0.17, 95% CI (0.04, 0.67), = 0.01].
Existing data show that acupuncture therapy has certain advantages in improving cognitive dysfunction and improving self-care ability of patients with Alzheimer's disease. However, due to the small number of RCTS and cases evaluating the efficacy of acupuncture, and the possibility of measurement bias and selectivity bias in included studies, it is still unable to conduct high-intensity demonstration on its effectiveness. Further large-scale, high-quality randomized, double-blind controlled trials are needed to evaluate its efficacy.
https://inplasy.com/inplasy-2021-12-0125/, identifier: INPLASY2021120125.
通过Meta分析系统评价针刺治疗阿尔茨海默病(AD)认知障碍的疗效,为针刺疗法在AD临床治疗中的应用提供循证依据。
从数据库建库至2022年12月31日,系统检索中国生物医学文献数据库(CBM)、中国知网(CNKI)、维普数据库、万方数据库、Pubmed、Embase和Cochrane图书馆数据库。收集已发表的针刺治疗AD认知障碍的随机对照临床试验(RCT)。干预组受试者单独接受针刺治疗或与对照组相同的其他治疗方法联合使用;对照组接受西医常规治疗。研究的主要结局指标为受试者的认知功能评估,包括:简易精神状态检查表(MMSE)、日常生活能力评定量表(ADL)、阿尔茨海默病认知功能评定量表(ADAS-Cog)、中医证候评分(SDSD)、蒙特利尔认知测试(MoCA),次要结局指标为不良反应的发生情况。由两名研究人员根据Cochrane手册推荐的偏倚风险评估工具,对纳入文献进行独立的文献筛选、数据提取和质量评价。采用RevMan5.3软件进行数据分析。二分类变量以风险比(OR)和95%可信区间(CI)表示,连续性变量以均数差(MD)和95%CI表示。对于异质性分析,当I²>0.1且Tau²≤50%时,应用固定效应模型。当I²≤0.1且Tau²>50%时,应用随机效应模型。
18项RCT共纳入1172例合格受试者,其中干预组595例,对照组577例。Meta分析结果如下:针刺干预组在改善MMSE[MD = 1.67,95%CI(0.94,2.41),P<0.00001]、ADL[MD = -1.18,95%CI(-3.09,0.72),P = 0.22]、ADAS-Cog[MD = 3.31,95%CI(5.84,0.78),P = 0.01]、SDSD[MD = 2.40,95%CI(3.53,1.26),P<0.0001]、MoCA[MD = 4.80,95%CI(3.74,5.86),P = 0.04]方面均优于对照组。干预组未观察到与针刺相关的严重不良反应,且不良反应的发生率和严重程度均低于对照组,差异有统计学意义[OR = 0.17,95%CI(0.04,0.67),P = 0.01]。
现有数据表明,针刺疗法在改善阿尔茨海默病患者认知功能障碍及提高自理能力方面具有一定优势。然而,由于评估针刺疗效的RCT数量及病例数较少,且纳入研究存在测量偏倚和选择性偏倚的可能,仍无法对其有效性进行高强度论证。需要进一步开展大规模、高质量的随机双盲对照试验来评估其疗效。
https://inplasy.com/inplasy-2021-12-0125/,标识符:INPLASY2021120125。